Skip to main content
Displaying 25 - 36 of 49
Display:
12
24
48
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy